Edition:
United States

NxStage Medical Inc (NXTM.O)

NXTM.O on Nasdaq

24.39USD
3:06pm EDT
Change (% chg)

$-0.03 (-0.12%)
Prev Close
$24.42
Open
$24.46
Day's High
$24.68
Day's Low
$24.34
Volume
206,055
Avg. Vol
587,729
52-wk High
$26.07
52-wk Low
$13.49

Latest Key Developments (Source: Significant Developments)

NxStage Medical Inc raises FY 2015 guidance; gives Q4 2015 guidance
Tuesday, 3 Nov 2015 07:28am EST 

NxStage Medical Inc:Expects FY 2015 revenue to be between $332 and $333 million, versus its previously increased guidance for revenue to be at the high end of its range of $324 to $328 million.Now expects FY 2015 net loss to be between $15 and $16 million, versus its previous guidance of $18 to $20 million, which was revised from its original guidance of $20 to $24 million.For the Q4 2015, the Company expects revenue to be in a range of $86 and $87 million, and a net loss in the range of $2 to $3 million.FY 2015 revenue of $327.8 million and net loss of $(20.1) million - Thomson Reuters I/B/E/S.Q4 2015 revenue of $85.9 million and net loss of $(3.71) million - Thomson Reuters I/B/E/S.  Full Article

NxStage and Spindial announce partnership with Niguarda-Ca' Granda Hospital in Milan
Friday, 11 Sep 2015 07:00am EDT 

NxStage Medical Inc:Announces their new partnership with the Niguarda-Ca' Granda hospital in Milan, Italy to help assist hemodialysis patients, including both current NxStage patients and non-NxStage patients, who wish to travel to Milan.  Full Article

NxStage Medical Inc sees FY 2015 revenue guidance to achieve at high end of prior guidance, lowers net loss guidance; gives Q3 2015 revenue guidance above estimates, net loss guidance below estimates
Thursday, 6 Aug 2015 07:45am EDT 

NxStage Medical Inc:Expects Q3 2015 revenue to be between $82 million and $83 million.Q3 2015 net loss in the range of $4.5 million to $5.5 million.Net loss guidance reflects expectations for continued operating income from the Products Business offset by the Company's continued investment in NxStage Kidney Care.Q3 2015 revenue of $81.8 million and net loss of $5.9 million - Thomson Reuters I/B/E/S.Expects FY 2015 to achieve the top end of prior revenue guidance between $324 and $328 million.Now expects FY 2015 net loss guidance in a range of $18 to $20 million versus previous guidance of net loss in the range of $20 to $24 million.FY 2015 revenue of $327.6 million and net loss of $22.7 million - Thomson Reuters I/B/E/S.  Full Article

NxStage Medical Inc sees FY 2015 revenue trending towards high end of prior guidance; gives Q2 2015 guidance
Wednesday, 6 May 2015 07:59am EDT 

NxStage Medical Inc:Says it expects FY 2015 revenue trending towards the higher end of guidance range which was originally set to be between $324 million and $328 million.Expects Q2 2015 revenue to be between $79.0 million and $80.5 million and a net loss in the range of $5.5 million to $7.0 million.  Full Article

NxStage Medical Inc gives FY 2015 mixed guidance; gives Q1 2015 guidance; earnings guidance below analysts' estimates
Thursday, 26 Feb 2015 07:27am EST 

NxStage Medical Inc:Forecasts FY 2015 revenue to be between $324.0 million and $328.0 million.Expects FY 2015 net loss in the range of $20.0 million to $24.0 million.Forecasts Q1 2015 revenue to be between $77.5 million and $78.5 million.Expects Q1 2015 net loss in the range of $6.5 million to $7.5 million.Majority of the company's projected net loss in both periods is expected to be related to the company's investment in NxStage Kidney Care.FY 2015 revenue of $323.9 million and net loss of $19.5 million - Thomson Reuters I/B/E/S.Q1 2015 revenue of $78.5 million and net loss of $5.2 million - Thomson Reuters I/B/E/S.  Full Article

NxStage receives FDA clearance for Home Nocturnal Hemodialysis
Monday, 22 Dec 2014 07:07am EST 

NxStage Medical Inc:Says that the U.S. Food and Drug Administration (FDA) has cleared its System One(tm) to perform hemodialysis overnight while the patient is at home sleeping, known as home nocturnal hemodialysis.NxStage's System One is the first and only hemodialysis machine cleared by the FDA for this indication.Company is actively preparing for full U.S. market launch in support of this expanded indication in 2015.The System One also is CE-marked for home nocturnal hemodialysis.  Full Article

NxStage Medical, Inc. raises FY 2014 revenue guidance and narrows earnings guidance; gives Q4 2014 guidance above analysts' estimates
Thursday, 6 Nov 2014 07:33am EST 

NxStage Medical, Inc:Expects FY 2014 revenue to be between $296-$298 mln, versus previous guidance of $290-$293 mln.Expects FY 2014 net loss to be between $24-$26 mln, versus previous guidance of $23-$27 mln.Expects Q4 2014 revenue to be in a range of $74.5-$76.5 mln.Expects Q4 2014 net loss in the range of $5-$7 mln.FY 2014 revenue of $292 mln and net income of $(26) mln - Thomson Reuters I/B/E/S.Q4 2014 revenue of $74.3 mln and net income of $(7.27) mln - Thomson Reuters I/B/E/S.  Full Article